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Background: To evaluate the outcomes of endoscopic retrograde 
cholangiopancreatography (ERCP) for malignant biliary obstruction (MBO) using 
short-type double-balloon enteroscope (sDBE) in patients with surgically altered 
anatomy. 
Methods: A total of 45 patients with surgically altered anatomy underwent ERCP 
using sDBE for the treatment of MBO between April 2011 and March 2019. We 
retrospectively evaluated the clinical and technical success (insertion and biliary 
intervention success), adverse events, and risk factors for clinical failure. 
Results: The scope was successfully inserted in the target site in 82.2% of patients 
(37/45), and among them, biliary intervention success was achieved in 86.4% (32/37). 
The overall technical success rate was 71.1% (32/45) and clinical success rate was 
68.9% (31/45), with an adverse event rate of 11.1%. In multivariate analysis, the 
presence of peritoneal dissemination (odds ratio, 7.3; 95% confidence interval, 1.5–
43.5, p=0.02) was as an independent risk factor for clinical failure. The clinical success 
rate was 38.5% in patients with peritoneal dissemination and 81.3% in those without 
peritoneal dissemination. 
Conclusion: Endoscopic treatment using sDBE in patients without peritoneal 
dissemination provided favorable outcomes, and it can be an initial treatment for MBO 
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Endoscopic biliary stent placement with endoscopic retrograde cholangiography 
(ERCP) for the treatment of malignant biliary obstruction (MBO) has been widely 
accepted as an effective drainage method because it is less invasive and safe and has a 
high success rate (1–3). However, MBO is treated using percutaneous transhepatic 
biliary drainage (PTBD) or surgical bypass because of difficulties related to endoscopic 
access to the bile duct following gastrointestinal reconstruction. However, these 
methods are associated with marked adverse event (AE) rates (1–3). 
 
Recently, balloon-assisted endoscopy (BAE) facilitates ERCP in patients with 
surgically altered anatomy. As for a double-balloon enteroscope (DBE), a short-type 
DBE (sDBE) is especially useful because it allows the use of many standard ERCP 
accessories. 
 
The success rates of reaching the target site and ERCP-related interventions 
associated using these endoscopes range from 73–100% and 85–100%, respectively (4, 
5). We previously reported that the success rate of reaching the target site and biliary 
intervention was 93.8% and 95.7%, respectively, in patients with benign 
hepaticojejunostomy (HJ) anastomotic stricture (6). 
 
However, inaccessibility of the target site may occur due to severe postoperative 
adhesions or a long insertion time (i.e., >60 minutes). Furthermore, previous reports 
have shown that the success rate of BAE in MBO cases was significantly lower than 
that in benign biliary diseases (7, 8). Few reports have investigated the outcome of 
BAE for MBO in patients with surgically altered anatomy. Additionally, the risk 
factors for clinical failure are not well-established. 
 
Thus, we retrospectively evaluated the outcomes of endoscopic treatment for MBO 





Between April 2011 and March 2019, 47 patients with MBO following gastrointestinal 
reconstruction underwent ERCP using sDBE for endoscopic biliary drainage at 
Okayama University Hospital. Indications for ERCP were clinical symptoms including 
fever, jaundice, and abdominal pain; elevated hepatobiliary enzyme levels; and/or 
dilation of the intrahepatic bile duct detected on abdominal ultrasonography or using 
radiological studies, such as computed tomography and magnetic resonance 
cholangiopancreatography. MBO was diagnosed by biopsy or brush cytology from the 
biliary stricture, or clinical/imaging follow-up indicated the progression or metastasis 
of a lesion with malignant symptoms, such as weight loss or death. Two patients who 
underwent PTBD before ERCP were excluded from this analysis. Therefore, a total of 
45 ERCP procedures using sDBE were considered eligible for inclusion. Informed 
consent was obtained from all subjects. The study protocol conformed to the ethical 
guidelines of the World Medical Association Declaration of Helsinki and was approved 
by The Okayama University Ethics Committee. 
 
ERCP procedures 
Patients were placed in a prone or semi-prone position. ERCP was performed under 
conscious sedation using intravenous diazepam (5–10 mg) and pethidine hydrochloride 
(35–140 mg) by an expert endoscopist who experienced at least 500 ERCP 
procedures using a side-view endoscope and 20 ERCP procedures using an sDBE or 
a non-expert supervised by an expert. An sDBE (EC-450BI5, EI-530B, or EI-580BT; 
Fujifilm, Saitama, Japan) was used. It was inserted in the afferent loop until it reached 
the target site (i.e., the major papilla or HJ anastomosis). After the scope reached the 
target site, biliary cannulation was performed using a 4-Fr tapered catheter (PR-
V234Q; Olympus) with a 0.025-inch guidewire (VisiGlide2; Olympus) in most cases. 
After cannulation, cholangiography was performed to confirm the presence of MBO, 
and the guidewire was manipulated again through the MBO. Then, we inserted 7-Fr 
plastic stents or self-expandable metal stents (SEMS) in the target biliary duct based 
on the endoscopist’s discretion. Uncovered and fully covered SEMS were used for 
malignant hilar biliary obstruction and malignant distal biliary obstruction, 
respectively (Figure 1A–D). 
 
Assessment of clinical outcome 
Clinical outcome was evaluated based on the clinical and technical success (insertion 
and biliary intervention success), insertion and total procedure time, stent patency, 
and AE. Insertion success was defined as the success rate of reaching the target site. 
Biliary intervention success was evaluated depending on the completion of 
cholangiography and stent placement in the target biliary duct among patients who 
achieved insertion success. Technical success was defined as cases that achieved 
insertion and biliary intervention success. Clinical success was defined as improvement 
in the pretreatment liver function test results and patient’s clinical symptoms within 
28 days of stent placement. Stent patency was defined as the time from stent 
placement to recurrent biliary obstruction (RBO). RBO was defined as elevated liver 
enzyme levels or cholangitis with images showing bile duct dilatation. Patient death 
before stent occlusion was treated as censored data. Stent patency was calculated using 
the Kaplan–Meier method. AEs were evaluated in accordance with the American 
Society for Gastrointestinal Endoscopy lexicon for endoscopic AEs (9). 
 
Statistical analysis 
Non-continuous variables were compared using the χ2 test, while continuous variables 
were compared using the Wilcoxon rank-sum test. A p-value <0.05 was considered as 
statistically significant. To identify risk factors for clinical failure via endoscopic 
treatment of MBO in patients with surgically altered anatomy, factors with p-values 
<0.1 in a univariate analysis were analyzed using a multivariate logistic regression. 
The following variables were analyzed: sex; age (>67 years); etiology, cause, and 
location of MBO; presence of peritoneal dissemination; type of surgical anatomy; 
presence of major papilla; time from surgery to endoscopic treatment (>505 days); total 
bilirubin (>2.5 mg/dL); aspartate aminotransaminase (>80 IU/L); alanine 
aminotransferase (>72 IU/L); g-glutamyl transpeptidase (>364 IU/L); alkaline 
phosphatase (>1205 IU/L); and type of scope. Cut-off values were set at the median of 
all patients in each variable. Peritoneal dissemination was defined as the presence of 
peritoneal lesions such as peritoneal nodules and mesenteric thickening based on the 
CT image preoperatively. All statistical analyses were performed using the JMP 12 
software (SAS Institute Inc., Cary, NC, USA). Ranges of continuous variables were 




A total of 45 patients [29 men and 16 women; median age: 67 years (range, 59–75 
years)] with surgically altered anatomy who underwent ERCP using sDBE for MBO 
treatment were retrospectively evaluated in this study. Patients' characteristics are 
shown in Table 1. The most common etiology of MBO was malignant biliary disease. 
The type of MBO was mostly recurrent disease in 39 patients (86.7%), and peritoneal 
dissemination was seen in 13 cases (28.9%). 
 
Clinical outcome 
Endoscopic results are shown in Table 2. Among the 45 patients, insertion success was 
achieved in 82.2% of the patients (37/45). The median insertion time required to reach 
the target site was 17 minutes (range, 10–29 minutes). Among nine patients with 
unsuccessful insertion, three underwent Roux-en-Y (RY) HJ reconstruction, three 
underwent RY with gastrectomy, one underwent reconstruction via the modified 
Child’s method, and one underwent Billroth II with gastrectomy, and the insertion 
success rates for RYHJ, RY with gastrectomy, modified Child’s method, and Billroth II 
with gastrectomy were 66.7%, 76.9%, 94.4%, and 80.0%, respectively. In cases where 
the modified Child’s method was used, the insertion success rate tended to be high, but 
the change was not statistically significant (p=0.08); however, this may be due to the 
small sample size. Insertion failure was observed in four patients with malignant 
digestive tract obstruction, in three with severe adhesion of the afferent loop, in one 
with failure to identify the HJ anastomosis, and in one with small intestinal 
perforation. We did not reattempt scope insertion with another type of scope if we 
encountered any difficulties. Of the unsuccessful cases, five patients were treated 
using PTBD, one was treated using endoscopic ultrasound-guided biliary drainage 
(EUS-BD), one was managed conservatively, and the other one patient with perforation 
was surgically treated. Biliary intervention success was achieved in 32 of 37 patients 
(86.4%). The total procedure time was 66 minutes (range, 40–92 minutes). In five 
patients with unsuccessful biliary intervention, cannulation failure in the native 
papilla (n=3) and severe biliary stricture which hindered guidewire advancement to the 
target biliary duct (n=2) contributed to biliary intervention failure. Two patients were 
managed conservatively because of refusing to undergo PTBD and choosing palliative 
care for terminal cancer, while the remaining three required PTBD. Moreover, 
technical success was achieved in 71.1% of patients (32/45). Among them, one patient 
had unimproved jaundice and was managed conservatively. Finally, clinical success 
was achieved in 68.9% of patients (31/45). Risk factors for clinical failure via endoscopic 
treatment of MBO in patients with surgically altered anatomy were analyzed using 
logistic regression analyses (Table 3). In multivariate analysis, the presence of 
peritoneal dissemination (odds ratio, 7.3; 95% confidence interval, 1.5–43.5) (p=0.02) 
was as an independent risk factor for clinical failure. 
 
Endoscopic treatment details 
Among the 31 patients with clinical success, 14 patients received plastic stent (PS) 
deployment (PS group) and 17 received SEMS deployment (MS group) as an endoscopic 
treatment. Characteristics of each group are shown in Table 4. 
Among them, RBO occurred in seven patients in each group, and the median stent 
patency was 120 (range, 105–280 days) and 141 (104–271 days) days (p=0.43), in the 
PS and MS groups, respectively (Figure 2). The median survival time from endoscopic 
treatment was 144 days. 
 
Adverse events 
Adverse events were observed in five patients (11.1%), including mild pancreatitis in 
three, moderate in one, and severe small intestinal perforation in one. Intestinal 
perforation by the tip of scope—during stretching of the scope—occurred at the 
transverse part of duodenum in a case with a Billroth II reconstruction. This case 
underwent emergent pancreaticoduodenectomy for a pancreatic head tumor and an 
intestinal perforation, and the postoperative course was uneventful, whereas the 
other patients were successfully managed conservatively. The AE rate was 0% (0/19) 
for the Modified Child’s method, 23.1% (3/13) for RY with gastrectomy, 0% (0/9) for 
RYHJ, and 40% (2/5) for Billroth II with gastrectomy. For Billroth II with 
gastrectomy, the rate of AEs was significantly higher than rates for the other 
methods (p=0.03). Peritoneal dissemination was observed in 20% of cases with AEs 
and was not related to the frequency of AE (p=0.64). 
 
Discussion 
In this study, we assessed the outcomes of endoscopic treatment for MBO using sDBE 
in patients with surgically altered anatomy. The technical success rate of endoscopic 
treatment was 71.1% and clinical success rate was 68.9%, with an AE rate of 11.1%. 
This result was comparable to the previous report that showed a technical success rate 
of 78.3% (8). 
 
In this study, insertion failure occurred in 61.5% (8/13) of technical failure cases, and 
malignant digestive tract obstruction or severe adhesion caused difficulty in sDBE 
insertion to the target site. Among 8 patients with failed scope insertion, peritoneal 
dissemination was noted in 5 patients based on the CT image before endoscopy (62.5%). 
Furthermore, the presence of peritoneal dissemination in CT image prior to endoscopy 
was as an independent risk factor for clinical failure. The clinical success rate was 
38.5% in patients with peritoneal dissemination and 81.3% in those without 
peritoneal dissemination. Failure in these patients was managed using PTBD or 
EUS-BD as an alternative treatment. Thus, pre-procedural CT image is important 
to determine treatment decisions, such as the appropriate use of EUS-BD or PTBD. 
 
The results of this study revealed no difference in stent patency between the PS and 
MS groups. In general, it is believed that the MS group had a longer patency period 
than the PS group. However, the median survival time was 144 days, and many 
patients died before RBO. This may have caused no significant difference in the 
patency period between both groups. Therefore, stent selection should be based on the 
prognosis of each case. 
 
EUS-BD has been reported as an effective alternative biliary drainage technique after 
a failed standard ERCP (10). Recent systematic analyses have shown that the high 
technical success rate of this procedure (90–94.7%) is associated with a high AE rate 
(16.5–23.3%) (11–14). Moreover, in the report of Iwashita et al. that evaluated the 
outcome of EUS-BD for MBO in patients with surgically altered anatomy whose 
subjects were similar to this study, the technical success and AE rates were 95% and 
20%, respectively. As such, AEs associated with EUS-BD procedures remain important 
problems to be resolved. Our result showed that endoscopic treatment using sDBE in 
patients without peritoneal dissemination on CT image before the procedure provided 
favorable outcomes with regard to the procedural success and AE rates. Therefore, we 
proposed the use of ERCP with sDBE as an initial treatment of MBO in patients with 
surgically altered anatomy, if peritoneal dissemination was not seen on CT image prior 
to the procedure. If peritoneal dissemination was indicated before the procedure, it 
may be better to attempt PTBD or EUS-BD as the initial treatment. 
 
This study had some limitations. First, it was retrospective in nature and was 
performed in a single center. Second, the sample size was small. Third, this study had 
no control group. Therefore, a prospective study involving sufficient number of patients 
is required to confirm our results. 
 
In conclusion, this study evaluated the outcomes of endoscopic treatment of MBO using 
sDBE in patients with surgically altered anatomy. Peritoneal dissemination on a CT 
image is an independent risk factor for clinical failure of an endoscopic procedure. 
Without peritoneal dissemination, ERCP using sDBE can be an initial treatment for 
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Figure 1: A patient underwent endoscopic retrograde cholangiopancreatography using 
short-type double-balloon endoscope for obstructive jaundice following 
pancreaticoduodenectomy with reconstruction via the modified Child’s method for 
pancreatic ductal adenocarcinoma (PDAC). 
A: Computed tomography image revealed intrahepatic bile duct dilation caused by 
malignant biliary obstruction (MBO) of hepaticojejunostomy (HJ) anastomosis for local 
recurrence of PDAC (arrowhead). 
B: Endoscopic image revealed local recurrence of PDAC in HJ anastomosis. 
C: Cholangiogram showed approximately 10-mm long MBO. 
D: Two uncovered self-expandable metallic stents were deployed in the right and left 
hepatic duct using the stent in stent method. 
 
Figure 2: Comparison of the cumulative stent patency after the treatment between the 
plastic stent (PS) (dotted line) and MS (solid line) groups. No significant difference was 
noted in stent patency between the groups (p=0.43). 
 
